Important disclaimer: This is general educational information, not medical advice. Erectile dysfunction is often a medical condition linked with heart disease, diabetes, blood pressure, hormones, and mental health. For a clear, neutral overview of ED and its causes, see MedlinePlus: Erectile Dysfunction .
When a supplement claims “clinically proven,” the obvious question is: what does the science actually show? VigRX Plus is one of the few male enhancement supplements that has been tested in a randomized, double-blind, placebo-controlled clinical trial on men with erectile dysfunction (ED).
In this deep-dive, we’ll walk through:
- How the VigRX Plus clinical study was designed ⚙️
- Who took part and what dose they used
- The actual numbers: IIEF scores, satisfaction, and safety
- Strengths, weaknesses, and what this trial can and cannot prove
- How it fits into broader ED research and medical guidelines
Want to review VigRX Plus current formula, pricing, bundles, and refund terms?
Visit VigRX Plus Official SiteWhy Clinical Evidence Matters for ED Supplements
Erectile dysfunction (ED) is defined as the persistent inability to get or keep an erection firm enough for satisfying sexual activity. It becomes more common with age but is not an inevitable part of aging. ED is also closely linked with conditions like cardiovascular disease, diabetes, high blood pressure and obesity.
Mainstream medical guidelines (such as those from the American Urological Association) recommend:
- Identifying and treating underlying diseases (diabetes, cardiovascular disease, hormonal issues)
- Lifestyle changes (weight, smoking, exercise, alcohol)
- Evidence-based treatments such as PDE5 inhibitors (e.g., sildenafil/Viagra) as first-line pharmacologic therapy
These guidelines do not endorse herbal supplements as standard first-line treatments, mainly because most have little or no robust clinical trial data.
That’s why the VigRX Plus randomized trial is interesting: it attempts to evaluate a commercial herbal blend using the same kind of methodology used for prescription drugs.
What Exactly Is VigRX Plus?
VigRX Plus is a proprietary multi-herb supplement marketed for male sexual enhancement (erection quality, libido, stamina, satisfaction). It’s an “updated” version of an earlier formula (VigRX) that already included herbs like:
- Panax ginseng (Korean red ginseng)
- Ginkgo biloba
- Tribulus terrestris
- Epimedium (icariin)
- Damiana and others
Pre-clinical work (animal studies and lab experiments) suggested these herbs may positively influence erection pathways, sexual behavior, and vascular function. :contentReference[oaicite:4]{index=4} But animal and in vitro data alone are not enough — hence the human clinical trial.
The VigRX Plus Clinical Study at a Glance
The main human trial on VigRX Plus was published in a peer-reviewed journal (BMC Complementary and Alternative Medicine, now part of BMC Complementary Medicine and Therapies).
Key facts:
- Study type: Randomized, double-blind, placebo-controlled, parallel-group
- Registration: Clinical Trials Registry – India (CTRI/2009/091/000099)
- Location: Outpatient clinics of urologists and general physicians in India
- Duration: 12 weeks
- Participants: 78 men aged 25–50 years with mild to moderate ED (based on IIEF erectile function scores)
- Groups: 39 received VigRX Plus (VXP), 39 received placebo
- Dosing: 2 capsules, twice daily (each capsule contained 360 mg of active or placebo blend)
All participants had erectile difficulties for at least two years and were not allowed to use other ED treatments during the study. Men with major illnesses such as diabetes, cardiovascular disease, or ED caused by surgery, medications or anatomical issues were excluded. :contentReference[oaicite:6]{index=6}
How Did Researchers Measure “Improvement”?
The trial used patient-reported questionnaires that are widely accepted in sexual medicine:
- International Index of Erectile Function (IIEF) – a validated 15-item questionnaire that measures:
- Erectile Function (EF)
- Orgasmic Function
- Sexual Desire
- Intercourse Satisfaction
- Overall Satisfaction
- Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) – completed by both men and their partners to rate satisfaction with the treatment.
The primary outcome was the change in the IIEF erectile function (EF) domain score from baseline to week 12. The EF domain ranges from 6 to 30; higher scores indicate better erectile function. :contentReference[oaicite:7]{index=7}
Clinically, EF scores are often grouped as:
- 26–30: No ED
- 22–25: Mild ED
- 17–21: Mild-to-moderate ED
- 11–16: Moderate ED
- 6–10: Severe ED
So a change of several points in the EF domain can be meaningful — it can move someone from “moderate” toward “mild” ED or even into the “no ED” range.
⚕️ Who Took Part? Inclusion & Exclusion Criteria
Men were eligible if they: :contentReference[oaicite:9]{index=9}
- Were 25–50 years old
- Reported sexual difficulties and scored 11–23 on the IIEF-EF domain (mild to moderate ED)
- Had no major medical conditions like diabetes or significant cardiovascular disease
- Were not taking medications known to cause ED
- Provided informed consent
Men were excluded if they had:
- Severe systemic illnesses
- ED due to anatomical, surgical, or drug-induced causes
- Recent use of another ED treatment (they had to go through a wash-out period)
In total, 78 men were randomized: 39 to VigRX Plus (VXP) and 39 to placebo. All VXP participants completed 12 weeks; three placebo participants dropped out (one withdrew consent, two were lost to follow-up). :contentReference[oaicite:10]{index=10}
Randomization, Blinding & Dosing
To limit bias:
- Randomization was performed in blocks using a concealed sequence.
- Both patients and investigators were blinded — VigRX Plus and placebo looked and tasted the same.
- Each participant took 2 capsules twice daily (total 4 capsules/day) for 12 weeks.
- Compliance was monitored via study visits and pill counts.
The analysis used standard statistical methods (ANCOVA and t-tests) and included both safety and per-protocol efficacy populations. :contentReference[oaicite:11]{index=11}
Key Results: Erectile Function & Sexual Satisfaction
1️⃣ Erectile Function (Primary Outcome)
After 12 weeks:
- The VigRX Plus group had a mean increase of 9 points in the IIEF-EF domain score (± 4.95).
- The placebo group improved by only 0.61 points (± 2.43).
- This difference was highly statistically significant (p < 0.0001). :contentReference[oaicite:12]{index=12}
Clinically, a 9-point jump in EF can shift a man from “moderate ED” into “mild” or even “no ED,” depending on where he started.
Specific IIEF items also showed improvement:
- “Erections hard enough for penetration” (Q2): 34% of VigRX Plus users vs 3% of placebo users said their erections were “almost always or always” hard enough for penetration.
- Ability to penetrate (Q3): increased by about 59% in the VigRX Plus group vs 4% in placebo.
- Maintaining erection after penetration (Q4): increased by 63% vs 9% in placebo. :contentReference[oaicite:13]{index=13}
By the end of the study, 14 out of 39 men in the VigRX Plus group achieved an EF score > 25 (i.e., into the “no ED” range), compared with just one subject in the placebo group. :contentReference[oaicite:14]{index=14}
2️⃣ Other IIEF Domains
VigRX Plus users also experienced statistically significant improvements in all other IIEF domains versus placebo: :contentReference[oaicite:15]{index=15}
- Sexual Desire (SD)
- Orgasmic Function (OF)
- Intercourse Satisfaction (IS)
- Overall Satisfaction (OS)
The largest gains were in erectile function and intercourse satisfaction. Total IIEF score increased by about 20 points in the VigRX Plus group vs only about 1 point in the placebo group. :contentReference[oaicite:16]{index=16}
3️⃣ Treatment Satisfaction (EDITS)
Both men and their partners rated satisfaction with treatment using the EDITS questionnaire. At 12 weeks: :contentReference[oaicite:17]{index=17}
- Significantly higher satisfaction scores were reported in the VigRX Plus group compared with placebo (p < 0.0001).
- 90% of VigRX Plus users said they would take the product again if they experienced similar problems in the future, vs 3% in the placebo group.
4️⃣ Semen Parameters & Testosterone
Despite marketing claims around fertility or testosterone, the trial found no significant differences between VigRX Plus and placebo in:
- Sperm count
- Semen volume
- Sperm motility
- Serum testosterone levels
So, based on this trial alone, improvements were mainly in erectile function and sexual satisfaction, not in measurable fertility or hormonal parameters. :contentReference[oaicite:18]{index=18}
️ Safety & Side Effects in the Study
Over the 12-week trial: :contentReference[oaicite:19]{index=19}
- A total of 23 adverse events were reported (11 in the VigRX Plus group, 12 in the placebo group).
- The most common event in both groups was mild fever.
- One serious adverse event (malaria) occurred in the VigRX Plus group, but it was not considered related to the product.
- Most participants in both groups rated tolerability as “very good.”
The authors concluded that VigRX Plus was “well tolerated” over 12 weeks in this relatively young, screened population of men with mild to moderate ED.
However, 12 weeks is still a short timeframe, and the trial did not investigate long-term cardiovascular outcomes or use in older men with multiple health conditions. For safety, that’s a big limitation.
How Big Is a 9-Point IIEF-EF Change?
A mean improvement of 9 points in the EF domain is substantial. For context, EF score changes of 4 points or more are often considered clinically meaningful in ED trials.
The authors compared their results with existing data on Korean red ginseng, a well-studied herbal remedy for ED:
- Ginseng trials have shown improvements of around 4–5 points on ED scales compared with placebo.
- VigRX Plus, which includes ginseng plus other herbs, showed a larger 9-point increase. :contentReference[oaicite:22]{index=22}
Meta-analyses of herbal supplements for ED suggest that some ingredients, such as ginseng, L-arginine, and Tribulus terrestris, can improve erectile function in mild to moderate ED — but the quality of evidence is generally rated as low to moderate, and many products are under-dosed or poorly studied.
VigRX Plus stands out mainly because:
- It has at least one reasonably well-conducted RCT.
- The effect size on a validated scale (IIEF-EF) is notably greater than placebo.
That said, one positive trial is still very far from the level of evidence we have for standard ED drugs like sildenafil, tadalafil, etc.
⚖️ Strengths of the VigRX Plus Clinical Trial
From an evidence perspective, the study has several strengths:
- Randomized, double-blind, placebo-controlled design – reduces bias and placebo effects.
- Pre-registration in a trial registry – adds transparency. :contentReference[oaicite:24]{index=24}
- Use of validated questionnaires (IIEF, EDITS) widely accepted in sexual medicine research. :contentReference[oaicite:25]{index=25}
- Good adherence: almost all participants completed the 12-week course.
- Consistent improvements across multiple domains (erection quality, desire, satisfaction).
- Similar adverse event rates in active and placebo groups, suggesting short-term tolerability.
Limitations & Sources of Bias
This is where it’s vital to be cautious. The authors themselves list several limitations, and from an evidence-based viewpoint, they’re important: :contentReference[oaicite:26]{index=26}
- Small sample size: Only 78 men, with 39 per group, is modest. Small trials are more vulnerable to random variation and overestimation of effect sizes.
- Short duration: 12 weeks is long enough to see early effects but not long enough to answer long-term safety or sustained efficacy questions.
- Unusual population: The study involved relatively young men (25–50) without significant comorbidities, whereas ED is most common in older men with diabetes, hypertension, and cardiovascular disease.
- Unclear ED causes: The trial did not clearly distinguish between psychogenic, organic, or mixed ED, limiting how precisely we can apply the results.
- Very low placebo response: Placebo effect in ED trials is often around 25% or higher, but in this study it was much smaller, which may exaggerate the apparent benefit of VigRX Plus.
- Industry involvement: The trial was conducted for a commercial supplement (VigRX Plus) and supported by a contract research organization that advertises this study as a “success story” for the sponsor, indicating potential conflicts of interest.
None of these limitations invalidate the study, but they do mean: one small, industry-sponsored trial should be viewed as promising but preliminary evidence, not definitive proof.
How Does This Fit into the Bigger ED Evidence Landscape?
Large guidelines and reviews emphasize that ED is a medical condition that often reflects broader vascular and metabolic health. It’s associated with higher risks of heart disease and stroke, particularly in men under 45, and should trigger a proper medical evaluation. :contentReference[oaicite:28]{index=28}
Mainstream guidelines recommend:
- Assessment of cardiovascular risk and metabolic health
- Lifestyle interventions (weight, exercise, smoking cessation)
- Evidence-based medications like PDE5 inhibitors as first-line pharmacologic therapy
- Psychological/relationship support when needed
In contrast, the evidence for herbal and nutraceutical products remains mixed:
- A 2018 systematic review of herbal dietary supplements for ED found encouraging but limited evidence for some ingredients (like ginseng) but stressed that the quality of studies is often low and more rigorous research is required.
- A 2023 analysis of ED supplements noted that only a small fraction of products on the market are dosed or formulated in a way that matches positive research, with many blends having negligible doses or no solid evidence behind them.
VigRX Plus is therefore one of the better-documented supplements in this niche, but even so, its evidence base is still tiny compared to prescription drugs.
Practical Takeaways if You’re Considering VigRX Plus
Putting everything together, here’s a realistic summary of what the clinical trial suggests:
- In a small, 12-week trial, VigRX Plus improved erectile function scores, sexual satisfaction, and treatment satisfaction more than placebo in men aged 25–50 with mild to moderate ED.
- Short-term safety looked similar to placebo in this selected population, with no major differences in adverse events.
- The study did not show improvements in testosterone or semen parameters.
- The evidence is promising but preliminary: one trial, small sample, relatively young and healthy men, and industry involvement.
- ED can be a warning sign of cardiovascular disease or other health issues, so it’s important not to rely on supplements alone without medical evaluation.
If someone chooses to try a product like VigRX Plus, an evidence-informed approach would include:
- Discussing ED openly with a doctor or urologist
- Screening for underlying health problems (blood pressure, blood sugar, lipids, hormones if indicated)
- Reviewing medications that might contribute to ED
- Using supplements as a possible adjunct, not a replacement, for medical care and lifestyle changes
❓ FAQ: Is VigRX Plus “Clinically Proven”?
Q: Can VigRX Plus be called “clinically proven”?
A: It has one published randomized, double-blind, placebo-controlled clinical trial showing benefit on erectile function and satisfaction scores over 12 weeks, in a small, specific population. That’s more evidence than most supplements have — but far less than the body of evidence supporting first-line ED medications.
Q: Does the study prove it will work for everyone?
A: No. The results may not generalize to:
- Older men
- Men with diabetes, heart disease, or multiple comorbidities
- Men with severe ED
- Men taking certain medications
Q: Is it safe to take long term?
A: The study only lasted 12 weeks. Long-term safety and interactions with other medications were not evaluated, so ongoing medical supervision is still important.
✅ Bottom Line
The VigRX Plus clinical trial is a rare example of a commercial male enhancement supplement being tested under controlled conditions. The results show meaningful short-term improvements in erectile function and sexual satisfaction versus placebo in a small group of younger men with mild to moderate ED, with no major safety signals reported.
At the same time, the study’s limitations — small size, short duration, narrow population and industry sponsorship — mean that VigRX Plus should be considered a supplement with preliminary supportive evidence, not a guaranteed solution.
For anyone dealing with ED, the best strategy remains a combination of:
- Proper medical evaluation
- Addressing underlying health factors
- Evidence-based therapy (where appropriate)
- Optional, carefully chosen supplements as an add-on, not a replacement
Use the clinical data as one piece of your decision-making puzzle — not the whole picture.
